Drug Profile
Research programme: neurodegenerative disease therapeutics - Vybion
Alternative Names: INT 41; rAAV6-INT41Latest Information Update: 28 Aug 2021
Price :
$50
*
At a glance
- Originator Vybion
- Class Antibodies; Gene therapies; Immunotherapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Alzheimer's disease; Huntington's disease; Spinocerebellar degeneration
Most Recent Events
- 28 Aug 2021 No recent reports of development identified for preclinical development in Huntington's-disease in USA (Parenteral)
- 28 Aug 2021 No recent reports of development identified for research development in Alzheimer's-disease in USA (Parenteral)
- 28 Aug 2019 INT 41 is still in preclinical trials for Huntington's disease in USA (Parenteral) (Vybion pipeline, August 2019)